Obesity impacts mental health greatly. Psychological factors may influence the effectiveness of its treatment. This study aimed to compare symptoms of generalised anxiety disorder and depression among adult women across different weight categories. The study sample comprised 1105 adult women. The computer-assisted web interview (CAWI) utilising the seven-item Generalised Anxiety Disorders Scale (GAD-7) and the nine-item Patient Health Questionnaire (PHQ-9) was used. Both GAD-7 and PHQ-9 scores correlated positively with BMI (r = 0.121, p < 0.001 and r = 0.173, p < 0.001, respectively) and negatively with age (r = −0.106, p < 0.001 and r = −0.103, p < 0.001, respectively). Patients undergoing treatment with semaglutide scored lower for both anxiety symptoms (8.71 ± 6.16, p = 0.013) and depression symptoms (9.76 ± 6.37, p = 0.013). Women who underwent bariatric surgery screened less frequently for anxiety (8.03 ± 6.27, p = 0.002) but not for depression. An interdisciplinary approach involving mental health professionals within the therapeutic team can comprehensively address factors contributing to obesity development and treatment outcomes. Further investigation of semaglutide’s use is needed due to the promising evidence suggesting a positive effect on decreasing the severity of depression and anxiety symptoms to assess the direct or indirect character of this influence.

(1) Background: Causes of obesity are multifactorial and include genetic predisposition as well as behavioural, psychological, social, and hormonal influences. We aimed to compare adult women with normal weight, overweight, and obesity, with a focus on maladaptive eating behaviours, the presence of generalised anxiety disorder, and the severity of depression. Additionally, we explored the context of anti-obesity pharmacotherapy and the status of bariatric surgery. (2) Methods: The sample was composed of 1105 adult women. The following measures, through the Computer-Assisted Web Interview (CAWI), were used in the present study: the Three Factor Eating Questionnaire (TFEQ-R18), the 7-item Generalised Anxiety Disorders Scale (GAD-7), and the 9-item Patient Health Questionnaire (PHQ-9). (3) Results: All domains of the TFEQ-R18 had correlations with Body Mass Index (BMI). There was a weak negative association between BMI and Cognitive Restraint (r = −0.172, p < 0.001) and a weak positive relationship between BMI and Uncontrolled as well as Emotional Eating (r = 0.165, p < 0.001; r = 0.191, p < 0.001, respectively). Women who screened positive for anxiety scored lower in the Cognitive Restraint domain (10.11 ± 3.58, p = 0.042) and higher in the Uncontrolled Eating (12.69 ± 6.04, p < 0.001) and Emotional Eating (5.29 ± 2.75, p < 0.001) domains. Similarly, women screening positive for depression had lower scores in Cognitive Restraint (9.88 ± 3.61, p < 0.001) and higher scores in Uncontrolled Eating (12.64 ± 6.09, p < 0.001) and Emotional Eating (5.31 ± 2.71, p < 0.001). A significant association between liraglutide and semaglutide administration and Cognitive Restraint was observed. (4) Conclusions: Individualised treatment for obesity should consider the existing and confirmed association between maladaptive eating behaviours and generalised anxiety disorder, as well as the severity of depression influencing the BMI altogether. The use of anti-obesity pharmacotherapy needs further exploration because the evidence for the use of liraglutide and semaglutide in terms of positive associations with eating behaviours is encouraging.

Obesity management, whether lifestyle-based, pharmacological, or surgical, is frequently associated with gastrointestinal adverse effects (GI AEs) that may impact treatment adherence and patient quality of life. With the increasing use of incretin-based anti-obesity medications (AOMs), they have gained particular clinical relevance. This review aims to explore current evidence on the prevalence, underlying mechanisms, and management strategies for GI AEs associated with obesity therapies, with a particular focus on nausea, diarrhea, constipation, gastroesophageal reflux and cholelithiasis. A search of PubMed and Scopus was conducted for articles published between 2006 and 2025. Eligible studies included randomized controlled trials, observational studies, and narrative or systematic reviews reporting on GI AEs in the context of obesity treatments, especially those involving incretin-based AOMs. Clinical trial data on AOMs indicate that GI AEs are reported in 65–84% of patients treated with liraglutide, semaglutide or tirzepatide, with the most common being nausea and diarrhea. These symptoms are primarily attributed to altered gastric motility and hormone-mediated changes in appetite signaling. Preventive strategies such as slow dose titration, dietary counseling, and supportive medications are commonly recommended to support tolerability and treatment continuation. GI AEs remain a common and often underestimated barrier to effective obesity management. Early recognition and structured management are essential to long-term success. Clinicians should incorporate anticipatory counseling and shared decision-making at treatment initiation to set realistic expectations, optimize tolerability, and support adherence.

Background: Obesity has significant social implications, as individuals often face stigma, negative attitudes, prejudice, and social discrimination. This stigma not only leads to negative psychosocial outcomes but also deters people living with obesity from adopting healthy lifestyles and seeking healthcare services, ultimately compromising their overall health and wellbeing. The primary aim of this study was to assess attitudes and stigma related to anti-obesity pharmacotherapy (AOMs) among adult Polish women. A secondary aim was to evaluate whether age, BMI, and a history of AOM use were associated with these outcomes. Methods: In this cross-sectional study, 1,043 adult women residing in Poland completed a computer-assisted web interview (CAWI) using a proprietary questionnaire adapted from established stigma scales. Participants were recruited via social media groups focused on lifestyle change and healthcare. Associations with age, BMI, and AOM use history were analyzed using non-parametric tests and Spearman correlations. Results: Older age was associated with more stigmatizing attitudes toward obesity and AOM use, while younger age was linked to more favorable views. Higher BMI was associated with greater self-stigma among AOM users. A positive history of AOM use was consistently associated with lower stigma, with the lowest levels observed among current users. Conclusions: Personal experience with AOM use is associated with more favorable attitudes toward pharmacotherapy and lower self-stigma, whereas younger age among AOM users is linked to greater experienced stigma. These findings highlight the importance of public education that frames obesity as a chronic disease and clarifies the evidence-based role of AOMs, particularly for women without personal experience of AOM use.

Background: Insomnia and excessive sleepiness are significant health problems with a complex etiology, increasingly affecting young people, especially students. This study aimed to assess the prevalence of sleep disturbances and patterns of psychoactive drug use among female Polish students. We also explored the potential impact of the COVID-19 pandemic on sleep behaviors. We hypothesized that sleep disorders are common in this group, that medical students are more likely to experience insomnia and excessive sleepiness, and that the pandemic has exacerbated both sleep disturbances and substance use. Methods: This cross-sectional study utilized a custom survey designed using standardized questionnaires—the Athens Insomnia Scale and Epworth Sleepiness Scale—that was distributed online using the Computer-Assisted Web Interviewing method. A total of 11,988 responses were collected from 31 January 2016 to 1 January 2021. Inclusion criteria were being female, having a college student status, and giving informed consent. Results: Among the 11,988 participants, alcohol use declined after the pandemic began (p = 0.001), while sedative use increased (p < 0.001). Insomnia (AIS) was associated with study year, university profile, and field of study (p < 0.001), with the highest rates in first-year and non-medical students. It was more common among users of sedatives, psychostimulants, and multiple substances. No significant change in insomnia was found before and after the pandemic. Excessive sleepiness (ESS) peaked in first-year and medical students. It decreased during the pandemic (p < 0.001) and was linked to the use of alcohol, psychostimulants, cannabinoids, and multiple substances. Conclusions: These findings highlight that female students are particularly vulnerable to sleep disorders. The influence of the COVID-19 pandemic on sleep disturbances remains inconclusive. Given the varied results in the existing literature, further research is needed.